Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 203

1.

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.

Hamid O, Hoffner B, Gasal E, Hong J, Carvajal RD.

Cancer Immunol Immunother. 2017 Jul 15. doi: 10.1007/s00262-017-2025-8. [Epub ahead of print] Review.

PMID:
28712033
2.

Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.

Komatsubara KM, Jeter J, Carvajal RD, Margolin K, Schadendorf D, Hauschild A.

Am Soc Clin Oncol Educ Book. 2017;37:641-650. doi: 10.14694/EDBK_175265.

3.

Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Komatsubara KM, Carvajal RD.

Curr Oncol Rep. 2017 Jul;19(7):45. doi: 10.1007/s11912-017-0606-5. Review.

PMID:
28508938
4.

Adopting a new stance on immunotherapy for uveal melanoma.

Komatsubara KM, Carvajal RD.

Lancet Oncol. 2017 Jun;18(6):702-704. doi: 10.1016/S1470-2045(17)30254-1. Epub 2017 Apr 7. No abstract available.

PMID:
28395881
5.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS.

Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079.

6.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Mar 17. doi: 10.1158/1078-0432.CCR-16-3068. [Epub ahead of print]

PMID:
28314788
7.

Patient perspectives on ipilimumab across the melanoma treatment trajectory.

Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, Goodman-Davis N, Colgan MN, Jefferson IS, Munhoz R, D'Angelo S, Wolchok J, Chapman P, Chi P, Carvajal RD, Hay JL.

Support Care Cancer. 2017 Jul;25(7):2155-2167. doi: 10.1007/s00520-017-3621-z. Epub 2017 Mar 1.

PMID:
28247127
8.

Uveal melanoma: epidemiology, etiology, and treatment of primary disease.

Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD.

Clin Ophthalmol. 2017 Jan 31;11:279-289. doi: 10.2147/OPTH.S89591. eCollection 2017. Review.

9.

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengeløv L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W.

J Clin Oncol. 2017 Jan;35(1):40-47. Epub 2016 Oct 31.

PMID:
28034081
10.

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.

D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD.

Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22.

PMID:
28007774
11.

Update on the treatment of uveal melanoma.

Carvajal RD.

Clin Adv Hematol Oncol. 2016 Oct;14(10):768-770. No abstract available.

PMID:
27930627
12.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.

Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD.

J Cancer Res Clin Oncol. 2017 Mar;143(3):439-445. doi: 10.1007/s00432-016-2318-x. Epub 2016 Dec 5.

PMID:
27921276
13.

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, Carvajal RD.

Melanoma Res. 2017 Feb;27(1):57-64. doi: 10.1097/CMR.0000000000000306.

PMID:
27792058
14.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

PMID:
27533448
15.

Structural Modifications of Deoxycholic Acid to Obtain Three Known Brassinosteroid Analogues and Full NMR Spectroscopic Characterization.

Herrera H, Carvajal R, Olea AF, Espinoza L.

Molecules. 2016 Aug 27;21(9). pii: E1139. doi: 10.3390/molecules21091139.

16.

The promise and pitfalls of the many methods of plasma genotyping.

Komatsubara KM, Carvajal RD, Sacher AG.

Expert Opin Biol Ther. 2016 Nov;16(11):1313-1316. Epub 2016 Sep 12. No abstract available.

PMID:
27608417
17.

Metastatic disease from uveal melanoma: treatment options and future prospects.

Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD.

Br J Ophthalmol. 2017 Jan;101(1):38-44. doi: 10.1136/bjophthalmol-2016-309034. Epub 2016 Aug 29. Review.

18.

Proinflammatory environment and role of TNF-α in endometrial function of obese women having polycystic ovarian syndrome.

Oróstica L, Astorga I, Plaza-Parrochia F, Vera C, García V, Carvajal R, Gabler F, Romero C, Vega M.

Int J Obes (Lond). 2016 Nov;40(11):1715-1722. doi: 10.1038/ijo.2016.154. Epub 2016 Aug 29.

PMID:
27569685
19.

Melanoma driver mutations and immune therapy.

Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA.

Oncoimmunology. 2016 Mar 10;5(5):e1051299. doi: 10.1080/2162402X.2015.1051299. eCollection 2016 May.

20.

Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract.

Schiavone MB, Broach V, Shoushtari AN, Carvajal RD, Alektiar K, Kollmeier MA, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol Rep. 2016 Apr 14;16:42-6. doi: 10.1016/j.gore.2016.04.001. eCollection 2016 Apr.

Supplemental Content

Loading ...
Support Center